Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. - Fraslin AM; Aupérin A; Even C; Fayette J; Saada-Bouzid E; Lafond C; Geoffrois L; Bourhis J; Guigay J; Bonastre J (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2025)